StockData

Fortress Biotech vs Rockwell Medical

FBIO and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FBIO and RMTI compare

Fortress Biotech is the larger company, worth 2.3 times as much as Rockwell Medical ($62.9M against $27.2M).

Fortress Biotech grew revenue faster over the last twelve months (15.5% versus −21.1% for Rockwell Medical).

Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −7.3% at Rockwell Medical.

Rockwell Medical scores higher on the StockData Score (11 against 9 for Fortress Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFBIORMTI
Size and price
Market cap$62.9M$27.2M
Share price$1.71$6.76
Change, 1 year−31.3%−25.9%
Change, 5 years−96.0%−86.0%
Beta (5Y)0.72−0.02
Employees78157
StockData Score
Total score911 (better)
Valuation score13 (better)
Growth score11
Performance score33
Health score44
Dividend score00
Valuation
P/S0.9×0.4× (better)
P/B0.4× (better)0.8×
P/FCF–17.7×
FCF yield–5.7%
Fair value–$33.27
Margin of safety–79.7%
Growth
Revenue growth (TTM)15.5% (better)−21.1%
Revenue growth, 5Y average6.8% (better)2.2%
Profitability
Gross margin65.6% (better)17.7%
Operating margin−42.9%−6.5% (better)
Net margin163% (better)−7.3%
FCF margin–2.2%
Return on equity107% (better)−15.5%
Return on invested capital−261%−17.9% (better)
Financial health
Debt / equity0.21 (better)0.26
Interest coverage−3.0× (better)−4.0×
Current ratio3.96 (better)3.25
Altman Z-score−1.81 (better)−7.79
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.9%0.05%
Held by insiders31.6%100%
Insider net buying, 12 months–−$11.6K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.